Marshall Wace
DMAC icon

Marshall Wace’s DiaMedica Therapeutics DMAC Stock Holding History

Marshall Wace’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,200
Closed -$256K – 3302
2025
Q4 		$256K Sell
32,200
-6,862
-18% -$51.3K ﹤0.01% 2511
2025
Q3 		$268K Sell
39,062
-22,657
-37% -$123K ﹤0.01% 2472
2025
Q2 		$241K Buy
61,719
+42,890
+228% +$167K ﹤0.01% 2399
2025
Q1 		$71.4K Buy
+18,829
New +$108K ﹤0.01% 2519
2023
Q4 		– Sell
-26,745
Closed -$69K – 2256
2023
Q3 		$69K Buy
+26,745
New +$85.9K ﹤0.01% 2065
2022
Q1 		– Sell
-10,031
Closed -$38K – 3477
2021
Q4 		$38K Hold
10,031
– – ﹤0.01% 3611
2021
Q3 		$40K Sell
10,031
-145,631
-94% -$557K ﹤0.01% 2941
2021
Q2 		$693K Buy
155,662
+79,695
+105% +$653K ﹤0.01% 1980
2021
Q1 		$695K Buy
75,967
+16,096
+27% +$150K ﹤0.01% 1810
2020
Q4 		$607K Buy
+59,871
New +$328K ﹤0.01% 1389

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's DMAC Position: Q1 2026 in Review

Marshall Wace sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 32,200 shares — an estimated $256K sold.

Marshall Wace first reported a position in DMAC in Q4 2020 and held it in 10 quarters. The position peaked at $695K in Q1 2021. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Marshall Wace reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 32,200 DiaMedica Therapeutics shares in Q1 2026, an estimated $256K.
  • Marshall Wace first reported a position in DiaMedica Therapeutics in Q4 2020 and held it in 10 quarters.
  • Marshall Wace's DiaMedica Therapeutics position peaked at $695K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.